4 studies found for:    weill | Open Studies | "Carcinoma, Hepatocellular"
Show Display Options
Rank Status Study
1 Recruiting A Study of LY2157299 in Participants With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: LY2157299;   Drug: Sorafenib
2 Recruiting Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Condition: Unresectable Hepatocellular Carcinoma
Intervention: Device: TheraSphere
3 Recruiting Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Conditions: Colorectal Cancer;   Gastric Adenocarcinoma;   Esophageal Cancer;   Hepatocellular Carcinoma;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Ovarian Epithelial Cancer;   Carcinoma Breast Stage IV;   Hormone-refractory Prostate Cancer;   Pancreatic Ductal Adenocarcinoma;   Head and Neck Cancers- Squamous Cell;   Renal Cell Cancer;   Urinary Bladder Neoplasms;   Cervical Cancer;   Endometrial Cancer;   Follicular Thyroid Cancer;   Glioblastoma Multiforme
Intervention: Drug: IMMU-132
4 Recruiting Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Conditions: Multiple Myeloma;   Lymphoma, Large B-Cell, Diffuse;   Pleiotropic Pathway Modifier;   Glioblastoma;   Lymphoma;   Primary Central Nervous System Lymphoma (PCNSL)
Intervention: Drug: CC-122

Indicates status has not been verified in more than two years